Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

80.93 -1.46 (-1.77%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Merck and Ridgeback Announce Supply Agreement With UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression
From Merck & Co., Inc.
Via Business Wire
Accelerating Global Access
SOURCE: Merck & Co., Inc. 
Via 3BL Media
All Hands on Deck Against COVID-19
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3
From Merck & Co., Inc.
Via Business Wire
Merck to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Merck and Ridgeback's Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19
SOURCE: Merck & Co., Inc. 
Via 3BL Media
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy
From Merck & Co., Inc.
Via Business Wire
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan
From Merck & Co., Inc.
Via Business Wire
Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19
From Merck & Co., Inc.
Via Business Wire
Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir
From Merck & Co., Inc.
Via Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery
From Merck & Co., Inc.
Via Business Wire
Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine
From Merck & Co., Inc.
Via Business Wire
ADDING and REPLACING European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
From Merck & Co., Inc.
Via Business Wire
European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
From Merck & Co., Inc.
Via Business Wire
Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
Merck Issues $1 Billion Inaugural Sustainability Bond
From Merck & Co., Inc.
Via Business Wire
Merck Issues $1 Billion Inaugural Sustainability Bond
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Topics Bonds Emissions Intellectual Property
Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 10, 2021 – USA News Group – Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Merck Prices $8.0 Billion Debt Offering
From Merck & Co., Inc.
Via Business Wire
Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities
From Merck & Co., Inc.
Via Business Wire
Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection
From Merck & Co., Inc.
Via Business Wire
Merck Supports Hiring Our Heroes Corporate Fellowship Program
SOURCE: Merck & Co., Inc. 
Via 3BL Media
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
From Merck & Co., Inc.
Via Business Wire
Fighting for Health Equity From Inside the Health Care Industry
SOURCE: Merck & Co., Inc. 
Via 3BL Media
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
From Merck & Co., Inc.
Via Business Wire
Creating a New World in Minecraft for Students to Explore
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.